Objective: To evaluate the effect of zinc as an adjuvant therapy in radiologically confirmed pneumonia in children 2-24 months of age. Patients and Methods: We analyzed data of 212 children with pneumonia for whom chest X-ray films were available at enrollment and at least two radiologists agreed on the diagnosis of pneumonia. We compared the time to recovery in the two groups (n ¼ 121, zinc group and n ¼ 91, placebo group) using a Cox proportional hazards regression model. Results: Time to recovery was similar in both groups [median interquartile range: zinc, 84 h (64, 140 h); placebo, 85 h (65, 140 h)]. The absolute risk reduction for treatment failure was 5.2% (95% confidence interval: À4.8, 15.1) with zinc supplementation. Conclusion: There was no significant beneficial effect of zinc on the duration of recovery or risk of treatment failure in children with radiologically confirmed pneumonia.
I N T R O D U C T I O N
Pneumonia is the leading cause of death in children <5 years of age, accounting for $18% deaths in this age group [1] . The situation is of particular concern to India, which carries 20% of the global pneumonia burden. Community-based standardized case management has been shown to reduce mortality from pneumonia by 70% [2] . However, there is still a need for additional adjunctive therapy to further improve outcomes particularly in children with severe pneumonia. Zinc deficiency in children has been associated with an increased risk for developing pneumonia, diarrhea and growth retardation [3] . Zinc deficiency is prevalent in India; Umesh et al. (2016) reported that 43.8% of the children <5 years of age were deficient in zinc as per their crosssectional study across five states in India [4] . Zinc plays an important role in adaptive and innate immunity; it helps in maintaining integrity of epithelial cells, has an antioxidant property and reduces inflammatory changes [5] . These properties and zinc's proven role in diarrheal diseases and in management of severe acute malnutrition have created interest among researchers to look up its potential role in pneumonia [6] .
There is emerging but conflicting evidence of the role of zinc as an adjunct in the treatment of pneumonia. In a meta-analysis, prophylactic administration of zinc supplementation showed 19% reduction in the incidence of pneumonia, but whether children with pneumonia would substantially benefit from zinc supplementation still needs to be answered [3, 7, 8] . In contrast, there are reports from both developed and developing countries that fail to demonstrate any significant effect of zinc supplementation on the treatment of pneumonia [8] [9] [10] . Our primary study, a double-blind randomized controlled trial (RCT) to evaluate efficacy of zinc as an adjunct in the treatment of pneumonia in children 2-24 months of age, showed that while there was no effect of zinc supplementation on the outcome of severe pneumonia, there could be a possible benefit of zinc supplementation in the subset of children with very severe pneumonia [11] . We hypothesized that children 2-24 months of age with radiologically confirmed pneumonia would benefit from zinc as an adjunct to standard therapy.
Pneumonia etiology studies suggest that 30-50% of bacterial pneumonia cases are caused by Pneumococcus, and studies incorporating viral causes have shown that the respiratory syncytial virus is the leading viral cause, identified in 15-40% of hospitalized children [12] . It is possible that our primary study and other studies that evaluated the effect of zinc supplementation on childhood pneumonia using the WHO clinical case definition may have inadvertently enrolled cases mimicking pneumonia, e.g. viral bronchiolitis [13, 14] . Additionally, the WHO case definition used for defining pneumonia in most of these studies is not powered to differentiate between various causative agents, i.e. viral vs. bacterial, and there is a possibility that the causative agents may influence the effect of zinc supplementation [15, 16] . Given the relatively low rates of positive blood cultures in our primary studies and other studies, a radiological diagnosis of pneumonia may be a better indicator of possible bacterial etiology [15] [16] [17] . Therefore, we conducted this secondary analysis to evaluate the effect of zinc as an adjunct to standard therapy in radiologically confirmed pneumonia in children 2-24 months of age.
S U B J E C T S A N D M E T H O D S
The detailed methodology and results of our primary study have previously been published [11] ; a brief description is provided here.
Study design and setting
Our primary study was a randomized double-blind placebo-controlled trial designed to assess the efficacy of oral zinc supplementation as an adjunct therapy to standard treatment of pneumonia for Indian children aged 2-24 months [11] . This study was conducted between February 2007 and March 2010 in three tertiary care teaching hospitals in New Delhi, India: Lady Hardinge Medical College, Deen Dayal Upadhyay Hospital and the All India Institute of Medical Sciences. The study protocol was approved by the ethics committees of the participating centers and the funding organizations. A written informed consent was obtained from the parent or guardian of eligible patients in the presence of a witness for the primary study.
Inclusion criteria
The study subjects of the primary study [11] for whom chest X-ray films at enrollment were available and at least two radiologists agreed on the diagnosis of pneumonia using standard guidelines [16] were enrolled in this analysis. Pneumonia had been classified as severe or very severe based on the relevant WHO criteria at the time of admission [13] . Children were categorized as having severe pneumonia if they had fast breathing (>50 breaths/min in children 2 to <12 months of age or >40 breaths/ min in children !12 months of age), chest in-drawing and crepitations on chest auscultation. Children with signs of pneumonia who also exhibited cyanosis or any general danger sign (lethargy, inability to drink or convulsions) were categorized as having very severe pneumonia [14] .
Methods
In the primary study, enrolled children were randomly assigned in permuted blocks of size 6 to receive either zinc or a placebo using STATA software (version 9.0; StataCorp). After random assignment, attending physicians gave each child one tablet of 10 mg elemental zinc or a placebo dissolved in 3 ml of distilled water every 12 h until recovery (defined as the end of 24 h period without any clinical signs of pneumonia) or the completion of a 14 day treatment period, whichever was earlier. The placebo was supplied by the WHO (source from Nutriset). Dispersible tablets that were identical in color, taste and appearance and packed in identical-looking blister strips with or without zinc sulfate (10 mg elemental zinc; Nutriset) were provided by the WHO. The estimated average requirement for zinc is 0.6 mg/day (in children 7-12 months of age) and 1.6-7.45 mg/ day (in children 1-3 years of age) [18] . The dose of the zinc was adapted from the WHO-recommended doses of zinc in childhood diarrhea [19] .
Children were treated according to the Indian Academy of Pediatrics guidelines [20] in accordance with the standard of care that was provided at the study hospitals at that time. The chest X-ray films used in this analysis were the ones taken at the time of admission; any other radiographs the child might have received during their treatment course were not included in this sub-study.
Chest X-ray interpretation All chest X-ray films were read independently by three radiologists, who were unaware of the clinical diagnosis or the allocation groups. The chest X-ray films were interpreted using the standard WHO guidelines [16] . All available chest X-ray films were assigned one of the following diagnoses: suggestive of pneumonia, other infiltrate or no consolidation/ infiltration/effusion. The chest X-ray film was reported as 'suggestive of pneumonia' if it showed consolidation, pleural effusion associated with parenchymal infiltrate or significant pleural effusion obscuring the underlying lung pathology. Only those children in whom at least two radiologists agreed on the diagnosis of 'suggestive of pneumonia' were included in this secondary analysis [16] . Chest X-ray films in which the image quality prevented the ability to discern the presence or absence of features suggestive of pneumonia were labeled as uninterpretable.
Outcomes
The primary outcome, time to recovery, was calculated as the time from randomization until recovery [11] .
Treatment failure was the secondary outcome, and defined as a need to change antimicrobial therapy within 7 days of randomization, a need for intensive care (ventilator and/or inotropic support), withholding of the study intervention for worsening in clinical condition or death at any time within 14 days of randomization or a failure to recover by Day 14 [11] .
Statistical analysis
The data were managed using Microsoft Access and analyzed using STATA (version 11.0; StataCorp, College Station, TX). Time to recovery in the two groups was compared using a Cox proportional hazards regression model; hazard ratio (HR) >1 indicated a beneficial effect of zinc. We compared the proportion of treatment failures in the two groups, and the corresponding relative risk (RR) and risk difference. We also performed analysis of subgroups based on the severity of pneumonia.
Results
Chest X-ray films of 476 of 550 children were identified as interpretable. Among those, at least two readers agreed on the radiological findings in 377 (79%) study subjects; of these, 212 chest X-ray films were categorized as 'suggestive of pneumonia'. Table 1 shows the baseline characteristics of children with radiologically confirmed pneumonia in the zinc and placebo groups. The two patient groups showed insignificant difference with respect to baseline characteristics, including age, gender, clinical characteristics or laboratory markers of inflammation like leukocytosis, C-reactive protein (CRP) and blood cultures. In the current secondary analysis, the serum zinc levels at time of recovery in the zinc and placebo groups were 13.42 6 5.92 mmol/l (n ¼ 103) and 10.21 6 3.21 mmol/l (n ¼ 80), respectively; the mean difference was 3.21 [95% confidence interval (CI): 1.75-4.66] mmol/l; p < 0.0001. However, the CRP values at time of recovery in the zinc and placebo groups were comparable [7.2 6 7.7 mg/l (n ¼ 108) and 6.4 6 6.9 mg/l (n ¼ 82); p ¼ 0.33]. Fig. 1 ). The absolute risk reduction for treatment failure was 5.2% (95% CI: À4.8, 15.1) with zinc supplementation (Table 2, Fig. 1 ).
Clinical outcomes
In the stratified analysis, there was a trend toward reduction in the time to recovery by 17 h in children with very severe pneumonia in the zinc group [median (IQR): zinc, 89 h (64, 126 h); placebo, 106 h (66, 144 h)]; however, the difference was not statistically significant (Table 3 , Fig. 2 ).
Outcome measures with respect to mortality, need for intensive care and change in antibiotics were similar in the zinc and placebo groups (Tables  2 and 3 ).
D I S C U S S I O N
This secondary analysis of the data from an RCT to evaluate the effect of oral zinc as an adjunct to standard antibiotic treatment in radiologically confirmed pneumonia in children 2-24 months of age did not show any significant benefit in time to recovery or treatment failure. In a stratified analysis, there was a trend toward reduction in the time to recovery by 17 h in the zinc supplementation group in those with very severe pneumonia.
The findings of this secondary analysis are similar to that of our primary study and also in accordance with a study by Bansal et al. 2011 from Chandigarh, India, where no significant benefit in recovery was observed with zinc supplementation; their inclusion criteria included hospitalized children with severe acute lower respiratory tract infection diagnosed clinically [9] . Effect of zinc supplementation on radiologically confirmed pneumonia has been examined by Fataki et al.'s 2014 study, which reported no beneficial effect of zinc on the duration of hospitalization or the proportion of Tanzanian children who were hospitalized for <3 days; however, this trial was stopped prematurely because of a low enrollment rate [21] . A systematic review of four hospital-based RCTs addressing the therapeutic benefit of adding zinc to antibiotic therapy in the management of childhood pneumonia did not show advantage of zinc supplementation on time of recovery [22] . Three of these RCTs used clinical criteria, while one used either clinical or radiological pneumonia for subject enrollment. A recent meta-analysis including nine RCTs did not show any beneficial effect of zinc as an adjunct in the treatment of pneumonia, in terms of time to recovery or length of hospital stay in children <5 years of age [23] . Various definitions of pneumonia used in these RCTs were consistent with Integrated Management of Neonatal and Childhood Illness classification [24, 25] .
Our results are in contrast to other trials from Dhaka, Bangladesh and Kolkata, India [4, 5] , that reported some beneficial effects of zinc supplementation; these studies were based on clinical diagnoses of pneumonia. A study from Uganda showed reduced mortality in the zinc-supplemented group but failed to show difference in terms of recovery time [26] . The mortality benefit in this study was more pronounced in HIV-positive children. Our study population did not include HIV-infected children.
These contradictory results may be attributed to the use of the WHO criteria for defining severe pneumonia, which has a high sensitivity for lower respiratory tract infections but is not specific to bacterial pneumonia and can include a wide range of etiologies [14] . There might be a possibility of zinc acting in different ways depending on underlying etiology, e.g. bacterial vs. non-bacterial. However, currently, there are no reliable methods to document bacterial pneumonia, as blood cultures are positive in <10% of the bacterial pneumonias. Radiological diagnosis of pneumonia may be a surrogate indicator of possible bacterial etiology, and hence, it seems that inclusion of radiological and microbiological diagnosis while conducting such RCTs may resolve the existing controversies.
The limitations of this study include small number of children with radiologically confirmed pneumonia and even smaller numbers of children with very severe pneumonia. Determination of etiology of lower respiratory tract infections is challenging in children; attempts to demonstrate known pathogens causing lower respiratory tract infections (both viral and bacterial) would have given better insight in understanding the role of zinc in etiologyspecific pneumonias. Fever was defined as an axillary temperature !37.5 C.
e Zinc concentrations were available for 119 in the zinc and 90 in the placebo groups. f Number of children with serum zinc levels <9.2 mmol/l. No significant differences in baseline characteristics were observed between the two groups. Fig. 2 . Kaplan-Meir survival estimates for time to recovery in patients with very severe pneumonia in the zinc vs. placebo groups with radiologically confirmed pneumonia.
In conclusion, we did not find beneficial effect of zinc on the time to recovery or risk of treatment failure in children with radiologically confirmed pneumonia. However, there was a trend toward faster recovery with zinc supplementation in children with very severe pneumonia, and more controlled trials are warranted to elucidate this trend and curtail the significant mortality from pneumonia in resource-poor settings.
F U N D I N G
The World Health Organization, Geneva, Switzerland (NCH 05004) and Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA (GHS-A-00-03-00019-00).
